Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans.
The recognition of chronic kidney disease (CKD) as an important public health issue has fostered an increasing number of strategies to increase CKD awareness and to reduce both the prevalence and the complications of CKD. Despite these advances, end-stage renal disease (ESRD) and cardiovascular events remain the major complications of CKD. Although the ESRD epidemic is attributed in greater part to the increasing rate of diabetes, hypertension remains the second most common reported cause of ESRD and is present in approximately 90% of cases of diabetes-related ESRD. The disproportionately high prevalence of hypertension in ethnic minorities, as well as the difficulty of achieving adequate blood-pressure control in these populations, contributes substantially to the high rate of CKD progression and complications in these groups. Although the role of hypertension as a primary cause of CKD is debated, hypertension is commonly recognized as the most important CKD progression factor. Important differences have been reported in the degree and likelihood of blood-pressure response to antihypertensive medications between ethnic groups, but ethnicity seems to be less important as a determinant of clinical outcomes. In this Review we examine key ethnic variations in hypertensive CKD in terms of pathophysiology, response to antihypertensive therapy, clinical outcomes, and evidence-based recommendations for blood-pressure control, with an emphasis on African Americans.
Norris
Keith C
KC
Charles Drew University of Medicine and Science, Los Angeles, CA 90059, USA. keithnorris@cdrewu.edu
Tareen
Naureen
N
Martins
David
D
Vaziri
Nosratola D
ND
D001741:Black or African American; D002986:Clinical Trials as Topic; D006801:Humans; D006977:Hypertension, Renal / Q000453:epidemiology / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy*